The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
本发明涉及用于免疫治疗方法的肽、核酸和细胞。特别地,本发明涉及癌症的免疫治疗。此外,本发明还涉及肿瘤相关的细胞毒性T细胞(CTL)肽表位,单独或与其他肿瘤相关肽表位结合,作为刺激抗肿瘤免疫反应的疫苗组分的活性药物成分。本发明涉及几种新的肽序列及其变异体,这些序列来自人类肿瘤细胞的H
LA I类和H
LA II类分子,可用于制备疫苗组分,以引发抗肿瘤免疫反应。